Unovet Pharma Private Limited
Founded in 2013 and headquartered in Bihar, India.
2013 | Patna, Bihar (India) | Active
Unovet Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year, 6 Months
- Last Filing with ROC 31 Mar 2019
- Revenue Growth 12.99%
- Profit Growth 171.89%
- Ebitda -152.33%
- Net Worth 51.32%
- Total Assets 27.21%
About Unovet Pharma
Unovet Pharma Private Limited (UPPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 August 2013 and has a history of 11 years and six months. Its registered office is in Patna, Bihar, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Babi Kumari, Pankaj Kumar, and Vikas Kumar serve as directors at the Company.
Company Details
- Location
Patna, Bihar, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U52311BR2013PTC020863
- Company No.
020863
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Aug 2013
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Trading
Who are the key members and board of directors at Unovet Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Babi Kumari  | Managing Director | 01-Aug-2013 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Pankaj Kumar | Director | 01-Aug-2013 | Current |
| Vikas Kumar | Director | 29-Jul-2019 | Current |
Financial Performance of Unovet Pharma.
Unovet Pharma Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 12.99% increase. The company also saw a substantial improvement in profitability, with a 171.89% increase in profit. The company's net worth Soared by an impressive increase of 51.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unovet Pharma?
In 2017, Unovet Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Unovet Pharma?
Unlock and access historical data on people associated with Unovet Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unovet Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unovet Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.